These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25755177)

  • 1. Mobilisation of haematopoietic stem cells in paediatric patients, prior to autologous transplantation following administration of plerixafor and G-CSF.
    Patel B; Pearson H; Zacharoulis S
    Pediatr Blood Cancer; 2015 Aug; 62(8):1477-80. PubMed ID: 25755177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.
    Uy GL; Rettig MP; Cashen AF
    Expert Opin Biol Ther; 2008 Nov; 8(11):1797-804. PubMed ID: 18847313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
    Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can every patient be mobilized?
    DiPersio JF
    Best Pract Res Clin Haematol; 2010 Dec; 23(4):519-23. PubMed ID: 21130416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.
    Girbl T; Lunzer V; Greil R; Namberger K; Hartmann TN
    Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plerixafor enables successful hematopoietic stem cell collection in an extensively pretreated patient with testicular cancer.
    Saure C; Weigelt C; Schroeder T; Klärner V; Galonska L; Haas R; Kobbe G
    Acta Haematol; 2010; 124(4):235-8. PubMed ID: 21099212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plerixafor in poor stem cell mobilizers: the Belgian Compassionate Use Program.
    Selleslag D; Dierickx D; Breems DA; Huynh P; Van De Velde A; Meers S; Brouwer E; Mertens A
    Acta Clin Belg; 2011; 66(3):200-4. PubMed ID: 21837928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.
    Worel N; Fritsch G; Agis H; Böhm A; Engelich G; Leitner GC; Geissler K; Gleixner K; Kalhs P; Buxhofer-Ausch V; Keil F; Kopetzky G; Mayr V; Rabitsch W; Reisner R; Rosskopf K; Ruckser R; Zoghlami C; Zojer N; Greinix HT
    J Clin Apher; 2017 Aug; 32(4):224-234. PubMed ID: 27578390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis.
    Badar T; Dhakal B; Szabo A; Padmanabhan A; Johnson BD; Heidtke S; Esselmann J; Chhabra S; Hamadani M; Hari P; D'Souza A
    J Clin Apher; 2019 Dec; 34(6):686-691. PubMed ID: 31566813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plerixafor. Only for certain patients when G-CSF stem cell mobilisation fails.
    Prescrire Int; 2010 Aug; 19(108):156-8. PubMed ID: 20939442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial).
    Schmid A; Friess D; Mansouri Taleghani B; Keller P; Mueller BU; Baerlocher GM; Leibundgut K; Pabst T
    Leuk Lymphoma; 2015 Mar; 56(3):608-14. PubMed ID: 24884311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
    Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.
    De Clercq E
    Pharmacol Ther; 2010 Dec; 128(3):509-18. PubMed ID: 20826182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plerixafor: a peripheral blood stem cell mobilizer.
    Kessans MR; Gatesman ML; Kockler DR
    Pharmacotherapy; 2010 May; 30(5):485-92. PubMed ID: 20411999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.
    Cashen A; Lopez S; Gao F; Calandra G; MacFarland R; Badel K; DiPersio J
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1253-61. PubMed ID: 18940680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
    Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
    Transfusion; 2012 Aug; 52(8):1785-91. PubMed ID: 22304442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].
    Sancho JM; Duarte R; Medina L; Querol S; Marín P; Sureda A;
    Med Clin (Barc); 2016 Sep; 147(5):223.e1-223.e7. PubMed ID: 27374031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.
    Andreola G; Babic A; Rabascio C; Negri M; Martinelli G; Laszlo D
    Eur J Haematol; 2012 Feb; 88(2):154-8. PubMed ID: 21992403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.